AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 33140515
Drug: Paclitaxel 80
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 80 mg/m2 weekly for 12 doses followed by FAC/FEC
Trial: 33140515
Drug: Eribulin 1.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eribulin 1.4 mg/m2 on days 1 and 8 of a 21-day cycle for 4 cycles followed by FAC/FEC
Trial: 36384081
Drug: Low FODMAP
RxNorm normalized name: ProNourish Low FODMAP Enteral Suspension (French Vanilla)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low FODMAP diet (4 g/day)
Trial: 36384081
Drug: Moderate FODMAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate FODMAP diet (23 g/day)
Trial: 33504175
Drug: Cognitive Therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Therapy for Grief
Trial: 32553279
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) group, 80 kV with a NI of 25 and iohexol (350 mg I/ml)
Trial: 32553279
Drug: Further Low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further Low Dose (FLD) group, 80 kV with a NI of 30 and iomeprol (400 mg I/ml)
Trial: 32553279
Drug: Low Dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Dose (LD) group
Trial: 32553279
Drug: Further Low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Further Low Dose (FLD) group
Trial: 32553279
Drug: Conventional Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional Dose (CD) group, 100 kV with a NI of 25 and iohexol (350 mg I/ml)
Trial: 35894487
Drug: Oral NSAIDs
RxNorm normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral NSAIDs with 60 minutes wait
Trial: 36408023
Drug: Sugemalimab plus
RxNorm normalized name: Sugemalimab
DrugBank: Sugemalimab (DB16641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugemalimab plus chemotherapy (SC)
Trial: 36408023
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus chemotherapy (PC)
Trial: 616357443
Drug: VesiGel 0.06%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VesiGel 0.06% (40mg at 64mL gel; n=20)
Trial: 616357443
Drug: VesiGel 0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VesiGel 0.12% (80mg at 64mL gel; n=22)
Trial: 35368016
Drug: Kinesiology tape
RxNorm normalized name: kinesiology tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kinesiology tape decompression/fan application with standard therapy
Trial: 35368016
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy with no kinesiology tape (Control)
Trial: 35718440
Drug: 2% curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% curcumin gel
Trial: 34716525
Drug: Sequential group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential group (continuous circular lesions created counter-clockwise starting from the site of 6 o'clock)
Trial: 32619497
Drug: Metformin prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin prescription
Trial: 32619497
Drug: T2DM without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: T2DM without metformin prescription
Trial: 36384562
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (hydroxychloroquine, sulphasalazine, and methotrexate) (TRIPLE)
Trial: 37982966
Drug: Methotrexate monotherapy
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate monotherapy (MTX)
Trial: 35704559
Drug: Azithromycin (AZM:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin (AZM: 250mg), once-weekly weight-based dose of 1-5 tablets, taken orally.
Trial: 34413300
Drug: Neoadjuvant immune
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoadjuvant immune checkpoint inhibitors (ICIs)
Trial: 32571649
Drug: Low Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Level Laser Therapy (LLLT) with passive self-ligating brackets
Trial: 32571649
Drug: Low Level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low Level Laser Therapy (LLLT) with conventional brackets
Trial: 35817323
Drug: 12 Gy/4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 Gy/4 fractions/4 days (for sequential boost)
Trial: 34673895
Drug: 12 mg/d
RxNorm normalized name: EMSAM 12 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg/d of intravenous dexamethasone
Trial: 34673895
Drug: 6 mg/d
RxNorm normalized name: EMSAM 6 MG/Day 24HR Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg/d of intravenous dexamethasone
Trial: 32372161
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (5%) 4 times daily for 14 days
Trial: 32372161
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline solution (5%)
Trial: 32540553
Drug: Trastuzumab (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab (4 mg/kg, biweekly) plus oral capecitabine (1500 mg/daily) and cyclophosphamide (50 mg/daily)
Trial: 35279890
Drug: Brodalumab 210
RxNorm normalized name: BRODALUMAB 210MG/1.5ML INJ 1.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brodalumab 210 mg after brodalumab 140 mg or placebo
Trial: 35793047
Drug: Once-daily alogliptin/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily alogliptin/metformin combination tablet (alogliptin 25 mg/metformin 500 mg)
Trial: 35793047
Drug: Twice-daily anagliptin/metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily anagliptin/metformin combination tablet low dose (anagliptin 100 mg/metformin 250 mg)
Trial: 32066254
Drug: Lactobacillus rhamnosus
RxNorm normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus rhamnosus CRL1332, L. gasseri CRL1256 and CRL1320
Trial: 36353762
Drug: Amenamevir 1200
RxNorm normalized name: amenamevir
DrugBank: Amenamevir (DB11701)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Amenamevir 1200 mg
Trial: 33685864
Drug: Etelcalcetide 5
RxNorm normalized name: etelcalcetide 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etelcalcetide 5 mg thrice weekly
Trial: 33685864
Drug: Maxacalcitol 5
RxNorm normalized name: paricalcitol
DrugBank: Paricalcitol (DB00910)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Maxacalcitol 5 or 10 µg thrice weekly
Trial: 33761804
Drug: Open label
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Open label once daily subcutaneous vosoritide combined with standard of care
Trial: 35276810
Drug: Ferrous bisglycinate
RxNorm normalized name: FERROUS BISGLYCINATE
DrugBank: Ferrous bisglycinate (DB11210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous bisglycinate (equiv. iron 24 mg) with folinic acid and multivitamins (test group, n = 60)
Trial: 35276810
Drug: Ferrous fumarate
RxNorm normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ferrous fumarate (equiv. iron 66 mg, control group, n = 60)
Trial: 32833549
Drug: Routine Treatment
RxNorm normalized name: Peace Out Acne Hero Routine KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine Treatment (RT)
Trial: 34865586
Drug: G100 20
RxNorm normalized name: G100
DrugBank: G100 (DB17244)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G100 20 µg/dose
Trial: 35939812
Drug: Opioid Agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Opioid Agonist Therapy (OAT)
Trial: 35303190
Drug: Telephone-Delivered Acceptance
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telephone-Delivered Acceptance and Commitment Therapy (ACT) intervention for hazardous drinking
Trial: 32757446
Drug: Intravenous Meloxicam
RxNorm normalized name: Meloxicam
DrugBank: Meloxicam (DB00814)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Meloxicam
Trial: 34609029
Drug: Crocin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crocin (30 mg, two tablets of 15 mg per day for 8 weeks)
Trial: 33681988
Drug: AMH modulation
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: AMH modulation (recombinant human AMH protein supplementation during the secondary-to-early antral stage followed by neutralizing anti-human AMH antibody)
Trial: 34053095
Drug: Leaflet-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leaflet-based intervention ‘Hypos can strike twice’ provided by ambulance personnel
Trial: 34053095
Drug: Leaflet-based intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Leaflet-based intervention ‘Hypos can strike twice’
Trial: 38940435
Drug: Dupilumab 300
RxNorm normalized name: dupilumab 300 MG in 2 ML Auto-Injector
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dupilumab 300 mg weekly
Trial: 34076641
Drug: Buccal pedicle
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buccal pedicle flap
Trial: 32364756
Drug: TGC perfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TGC perfusion chemotherapy
Trial: 32364756
Drug: Sunitinib +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib + TGC perfusion chemotherapy
Trial: 35686189
Drug: Online remote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Online remote behavior therapy
Trial: 35686189
Drug: Face-to-face behavior
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face behavior therapy
Trial: 32856190
Drug: FA +
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FA + DHA (FA 800 μg/d + DHA 800 mg/d)
Trial: 32856190
Drug: FA (FA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FA (FA 800 μg/d)
Trial: 32856190
Drug: DHA (DHA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA (DHA 800 mg/d)
Trial: 36458132
Drug: 0.1% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1% menthol gel
Trial: 36458132
Drug: 0.3% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3% menthol gel
Trial: 36458132
Drug: 0.7% menthol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.7% menthol gel
Trial: 36458132
Drug: All menthol
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All menthol gels
Trial: 33431262
Drug: Pain-analgesics treatment
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-analgesics treatment
Trial: 33431262
Drug: Pain-no analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pain-no analgesics
Trial: 33431262
Drug: No pain-analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pain-analgesics treatment
Trial: 33431262
Drug: No pain-no
RxNorm normalized name: Biochemistry Heel No Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No pain-no analgesics
Trial: 34057124
Drug: Dorsata honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorsata honey (DH) given orally three times a day at a dose of 15 ml
Trial: 36113170
Drug: Intrathecal cell
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal cell treatments (NurOwn®)
Trial: 32507446
Drug: Phytosomal curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosomal curcumin (250 mg/day) for 8 weeks
Trial: 32424878
Drug: Mindfulness-based cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mindfulness-based cognitive therapy (MBCT-I)
Trial: 34980598
Drug: Fulvestrant plus
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant plus sapanisertib 4 mg daily
Trial: 34980598
Drug: Fulvestrant plus
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant plus sapanisertib 30 mg weekly
Trial: 34980598
Drug: Fulvestrant 500
RxNorm normalized name: Fulvestrant
DrugBank: Fulvestrant (DB00947)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Fulvestrant 500 mg (control)
Trial: 32127847
Drug: Intravenous ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous ondansetron weight adjusted dosing at 0.1mg/kg
Trial: 32127847
Drug: Fixed dose
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed dose of 4mg ondansetron
Trial: 34477818
Drug: Avelumab (anti-PD-L1)
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab (anti-PD-L1) administered at various doses: 70 mg, 350 mg, 500 mg every 2 weeks; 500 mg every 3 weeks; and 10 mg/kg every 2 weeks.
Trial: 34477818
Drug: Avelumab (anti-PD-L1)
RxNorm normalized name: Avelumab
DrugBank: Avelumab (DB11945)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Avelumab (anti-PD-L1) administered at various doses.
Trial: 33791349
Drug: Routine oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine oxygen therapy
Trial: 39082471
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (ACEi)
Trial: 32586079
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi exercise for 30 minutes, 5 times weekly for 48 weeks
Trial: 32586079
Drug: Tai Chi
RxNorm normalized name: Ma Chi Xian
DrugBank: Purslane (DB14327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tai Chi exercise for 60 minutes, 5 times weekly for 48 weeks
Trial: 32046755
Drug: Prophylactic augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prophylactic augmentation of the wound with absorbable mesh
Trial: 32957336
Drug: 10 days
RxNorm normalized name: AlleRx 10-day Dose Pack
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 days of standard triple therapy (STT) using ilaprazole (10 mg ilaprazole, 500 mg clarithromycin, and 1000 mg amoxicillin twice daily)
Trial: 32957336
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days of standard triple therapy (STT) using ilaprazole (10 mg ilaprazole, 500 mg clarithromycin, and 1000 mg amoxicillin twice daily)
Trial: 35148357
Drug: Empagliflozin 25
RxNorm normalized name: empagliflozin 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Empagliflozin 25 mg for 12 weeks
Trial: 36324245
Drug: MD-7246 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-7246 300 μg
Trial: 36324245
Drug: MD-7246 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-7246 600 μg
Trial: 36324245
Drug: MD-7246 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MD-7246 1200 μg
Trial: 33632268
Drug: Pediatric integrative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric integrative manual therapy (PIMT) combined with caregiver education program
Trial: 35043692
Drug: Hyperglycemia (≥180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperglycemia (≥180 mg/dL)
Trial: 35043692
Drug: Normoglycemia (<180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycemia (<180 mg/dL)
Trial: 33249498
Drug: Reduced nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced nicotine content (RNC) study cigarettes tapered every three weeks to a final VLNC (0.2 mg/cigarette) for six weeks
Trial: 33249498
Drug: Usual nicotine
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Usual nicotine content (UNC) study cigarettes (11.6 mg/cigarette)
Trial: 32236521
Drug: 4-Cl-KYN monotherapy
RxNorm normalized name: Decamethylenebis(4-aminoquinaldinium chloride)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-Cl-KYN monotherapy (1080 mg/d for 7 days, then 1440 mg/d for 7 days)
Trial: 35291408
Drug: Normal to
RxNorm normalized name: PROGAINE NORMAL TO DRY SHAMPOO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal to low blood pressure (MAP deliberately controlled at a tight limit from normal baseline MAP values to 20% less than baseline by titrating TNG infusion)
Trial: 32087031
Drug: Freeze-dried German
RxNorm normalized name: BLACKBERRY MESOCARP FREEZE DRIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Freeze-dried German chamomile tea capsules
Trial: 34111992
Drug: Landmark-guided injection
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Landmark-guided injection of 40 mg methylprednisolone plus 1 mL lidocaine
Trial: 34111992
Drug: Ultrasonography-guided injection
RxNorm normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasonography-guided injection of 40 mg methylprednisolone plus 1 mL lidocaine
Trial: 34111992
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between landmark-guided and ultrasonography-guided injections
Trial: 33164580
Drug: Nicotine e‐cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nicotine e‐cigarette (59 mg/mL)
Trial: 33164580
Drug: Placebo e‐cigarette
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo e‐cigarette (0 mg/mL)
Trial: 35321823
Drug: Ticagrelor in
RxNorm normalized name: Product containing ticagrelor in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor in addition to aspirin
Trial: 36270493
Drug: Ticagrelor in
RxNorm normalized name: Product containing ticagrelor in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticagrelor in addition to aspirin (THEMIS-PCI substudy)
Trial: 33962511
Drug: Osteopathic manipulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic manipulative treatment (OMT) including rib raising and suboccipital release in addition to standard asthma care.
Trial: 33077567
Drug: Exogenous surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous surfactant therapy (Curosurf, Chiesi Pharmaceuticals, Italy)
Trial: 33077567
Drug: Exogenous surfactant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exogenous surfactant therapy (Curosurf)
Trial: 34410414
Drug: Personalized antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personalized antiplatelet therapy (PFT-guided)
Trial: 33750034
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1000 mg twice daily for 14 weeks
Trial: 35567420
Drug: Test product
RxNorm normalized name: Patch test product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test product of rosuvastatin 10 mg
Trial: 35567420
Drug: Reference product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference product of rosuvastatin 10 mg
Trial: 35567420
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of rosuvastatin 10 mg
Trial: 34340936
Drug: Endometrial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial preparation with GnRH agonist pre-treatment (group A)
Trial: 34340936
Drug: Endometrial preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endometrial preparation without GnRH agonist pre-treatment (group B)
Trial: 36182028
Drug: N-acetyl cysteine
RxNorm normalized name: N-Acetyl Cysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl cysteine (NAC) 1200 mg TID
Trial: 35268481
Drug: Subetta therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subetta therapy for 12 weeks
Trial: 34534272
Drug: Ciraparantag 30
RxNorm normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag 30 mg
Trial: 34534272
Drug: Ciraparantag 60
RxNorm normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag 60 mg
Trial: 34534272
Drug: Ciraparantag 120
RxNorm normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag 120 mg
Trial: 34534272
Drug: Ciraparantag 30
RxNorm normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag 30 mg (rivaroxaban)
Trial: 34534272
Drug: Ciraparantag 60
RxNorm normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag 60 mg (rivaroxaban)
Trial: 34534272
Drug: Ciraparantag 120
RxNorm normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag 120 mg (rivaroxaban)
Trial: 34534272
Drug: Ciraparantag 180
RxNorm normalized name: Ciraparantag
DrugBank: Ciraparantag (DB15199)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciraparantag 180 mg (rivaroxaban)